Annals of Surgical Oncology

, Volume 11, Issue 10, pp 881–882 | Cite as

CD4 Help and Tumor Immunity: Beyond the Activation of Cytotoxic T Lymphocytes

Editorial

REFERENCES

  1. 1.
    Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–46.PubMedCrossRefGoogle Scholar
  2. 2.
    Murray JS. How the MHC selects Th1/Th2 immunity. Immunol Today 1998; 19: 157–63.PubMedCrossRefGoogle Scholar
  3. 3.
    Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297–322.PubMedCrossRefGoogle Scholar
  4. 4.
    Lowes MA, Bishop GA, Crotty K, et al. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108: 914–19.PubMedCrossRefGoogle Scholar
  5. 5.
    Wagner SN, Schultewolter T, Wagner C, et al. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression. Lab Invest 1998; 78: 541–50.PubMedGoogle Scholar
  6. 6.
    Goedegebuure PS, Lee KY, Matory YL, et al. Classification of CD4+ T helper cell clones in human melanoma. Cell Immunol 1994; 156: 170–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee KY, Goedegebuure PS, Linehan DC, Eberlein TJ. Immunoregulatory effects of CD4+ T helper subsets in human melanoma. Surgery 1995; 117: 365–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Hu HM, Urba WJ, Fox BA. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J Immunol 1998; 161: 3033–41.PubMedGoogle Scholar
  9. 9.
    Kobayashi M, Kobayashi H, Pollard RB, Suzuki F. A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 1998; 160: 5869–73.PubMedGoogle Scholar
  10. 10.
    Hung K, Hayashi R, Lafond-Walker A, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998; 188: 2357–68.PubMedCrossRefGoogle Scholar
  11. 11.
    Hsueh EC, Famatiga E, Shu S, Ye X, Morton DL. Peripheral Blood CD4+ T-Cell Response Before Postoperative Active Immunotherapy Correlates with Clinical Outcome in Metastatic Melanoma. Ann Surg Oncol 2004; 11: 892–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002; 20: 4549–54.PubMedCrossRefGoogle Scholar
  13. 13.
    Chung MH, Gupta RK, Hsueh E, et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 2003; 21: 313–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Perales MA, Blachere NE, Engelhorn ME, et al. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 2002; 12: 63–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Jaeger E, Bernhard H, Romero P, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996; 66: 162–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894–900.PubMedCrossRefGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2004

Authors and Affiliations

  1. 1.Clinical Immunology Service, Department of MedicineMemorial Sloan-Kettering Cancer Center and Joan and Sanford I Weill Medical College of Cornell UniversityNew York
  2. 2.Department of MedicineMemorial Sloan-Kettering Cancer CenterNew York

Personalised recommendations